Kymera Therapeutics, Inc.
$73.21
+0.72%Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -19.8).
Valuation inputs: P/E -19.8, earnings yield N/A, momentum +0.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -19.7%, ROIC -20.9%).
Profitability stack: net margin -7.9%, ROE -19.7%, ROIC -20.9%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +9.4%, momentum +0.7%, net margin -7.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Kymera Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Kymera Therapeutics, Inc. Fair Value Envelope
Kymera Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Kymera Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Kymera Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Balanced asset mix between current and non-current assets, typical of many stable businesses.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Kymera Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that KYMR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 119.93, with estimates ranging from a low of 106.00 to a high of 138.00.
The consensus 1-year price target stands at 119.93, with estimates ranging from a low of 106.00 to a high of 138.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Kymera Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $163.14M and sold $21.77M worth of KYMR shares, resulting in $141.36M of net buying activity.
3 Months
0
0.00
83.8K
6.90M
-6.9M
-$6.90M
3-6 Months
1.8M
158.12M
95.3K
8.10M
+150.0M
+$150.02M
6-9 Months
0
0.00
127.4K
6.54M
-6.5M
-$6.54M
9-12 Months
114.0K
5.01M
4.5K
225.00K
+4.8M
+$4.79M
Top Buyers
Baker Bros. Advisors Lp
Director, 10 Percent Owner:
$160.55M
Bvf Partners L P/Il
Director, Other: See Remarks And Footnotes
$2.59M
Top Sellers
Mainolfi Nello
Director, Officer: Chief Executive Officer
$6.71M
Chadwick Jeremy G
Officer: Chief Operating Officer
$4.63M
Jacobs Bruce N.
Officer: Chief Financial Officer
$3.96M
Booth Bruce
Director
$3.04M
Esposito Pamela
Director
$1.43M
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $141.36M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
KYMR has not reported any dividend yield values in the available annual periods.
kymr Dividend History
Learning Layer
Related Guides
Build conviction on KYMR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.